Seaport Therapeutics files for proposed IPO

Seaport Therapeutics has on Friday filed for a proposed Nasdaq IPO.

The company describes itself as: "We are a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies. Glyph is a lymphatic-targeting prodrug technology which is designed to bypass first-pass metabolism and thereby enhance a drug’s oral bioavailability and reduce side effects. This process, which we call “Glyphing,” also creates new composition of matter intellectual property. Our experienced team of industry leaders has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. We aim to develop novel, leading treatment options that will make a significant impact for patients and their families."

Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel will serve as underwriters.

You May Also Be Interested In

• UAE Says Situation Currently Safe After Potential Threat Alert
• SaverOne and VisionWave close $7M RF defense transaction
• Nicola Mining confirms porphyry copper target at New Craigmont project